Obstructive Jaundice — DCE Clinical Case

Long case

Patient scenario

Mr RH is a 68-year-old retired accountant referred by his general practitioner with four weeks of progressive yellowing of the skin and eyes, noticed first by his wife. He describes dark, tea-coloured urine, pale putty-coloured stools that are difficult to flush, and severe itching that wakes him at night. He has lost 7 kilograms over two months without trying, with reduced appetite and early satiety. He has had no abdominal pain, no fevers, and no rigors. His past medical history includes hypertension and diet-controlled type 2 diabetes diagnosed six months ago. He does not drink alcohol and has never smoked. There is no family history of pancreatic or gastrointestinal cancer. He has not taken any new medications; his only regular medications are ramipril and metformin. [1]

Recent investigations: bilirubin 210 micromol per litre (conjugated fraction 78 per cent), ALP 540 U per L (five times the upper limit of normal), GGT 380 U per L, ALT 95 U per L, AST 88 U per L. Full blood count normal. INR 1.6. CA 19-9 markedly elevated at 420 U per mL (reference range below 37). CEA mildly elevated. Contrast-enhanced triple-phase CT of the abdomen shows a 3 cm low-density mass in the head of the pancreas with dilatation of the common bile duct and pancreatic duct (the double-duct sign), no encasement of the superior mesenteric artery or vein, and no liver or peritoneal metastases. Ultrasound had initially shown gallstones but the distal CBD was not well visualised. [1]

Examination findings

The patient is alert and oriented but appears fatigued. He is deeply icteric with visible scratch marks on his forearms and back. He is afebrile, heart rate 82, blood pressure 134 over 82, respiratory rate 16, oxygen saturation 97 per cent on room air. There is no spider naevi, palmar erythema, or asterixis. Abdominal examination reveals a palpable, non-tender, smooth, distended gallbladder in the right upper quadrant (Courvoisier sign) and a firm, poorly defined mass in the epigastrium. There is no hepatosplenomegaly, no shifting dullness, and no ascites. Bowel sounds are normal. Rectal examination reveals pale clay-coloured stool that is guaiac-negative. There is no peripheral oedema and no lymphadenopathy, including no palpable Virchow's node. [1]

Candidate's opening statement (SASPOP)

"Doctor, my patient is Mr RH, a 68-year-old retired accountant with four weeks of painless progressive obstructive jaundice from a resectable pancreatic head mass. His problems are: obstructive jaundice with a bilirubin of 210, pale stools and dark urine, and severe pruritus; a 7-kilogram weight loss suggesting malignancy; Courvoisier sign and an epigastric mass on examination, both pointing to a malignant distal obstruction; a markedly elevated CA 19-9 at 420 consistent with pancreatic malignancy; a 3 cm pancreatic head mass with the double-duct sign on triple-phase CT, with no vascular encasement or metastases, classifying the tumour as resectable; and a new-onset diabetes and a coagulopathy (INR 1.6) from vitamin K malabsorption. My priorities are to obtain tissue confirmation by EUS-FNA, to exclude autoimmune pancreatitis with a serum IgG4, to correct the coagulopathy with vitamin K, to stage definitively with possible staging laparoscopy, and to proceed to pancreaticoduodenectomy with curative intent, without routine preoperative biliary drainage." [1]

Problem list

1. Obstructive (surgical) jaundice — pancreatic head mass, conjugated hyperbilirubinaemia, cholestatic LFTs.
2. Pancreatic ductal adenocarcinoma (probable) — resectable on CT staging [3].
3. Courvoisier sign and epigastric mass — strongly suggests malignancy over stone disease [5].
4. Coagulopathy (INR 1.6) — vitamin K malabsorption from biliary obstruction; corrects with vitamin K if hepatocytes intact.
5. Pruritus — bile salt deposition in skin; a major quality-of-life issue.
6. Weight loss and new-onset diabetes — paraneoplastic or direct endocrine effect of the tumour.

Integrated management plan

Tissue diagnosis. EUS-FNA of the pancreatic head mass to confirm adenocarcinoma. EUS has the highest sensitivity for pancreatic lesions and allows fine-needle aspiration with sensitivity of 85 to 92 per cent and specificity of 95 to 98 per cent [8]. This is essential before committing to surgery or neoadjuvant therapy.

Exclude mimics. Check serum IgG4 to exclude autoimmune pancreatitis (type 1, IgG4-related), which presents as painless obstructive jaundice with a pancreatic mass and is steroid-responsive. The cardinal error is operating on autoimmune pancreatitis for presumed cancer. [1]

Correct the coagulopathy. Give vitamin K 10 mg intravenously for the INR of 1.6. The INR should correct within 24 to 48 hours if the hepatocytes are intact; failure to correct would suggest hepatocellular failure and worsen the prognosis. Check the INR before any invasive procedure. [1]

Staging and resectability. Triple-phase CT has confirmed resectability (no vascular encasement, no metastases). Perform staging laparoscopy immediately before laparotomy to exclude occult peritoneal and liver metastases that would render the Whipple futile. If all is clear, proceed to pancreaticoduodenectomy with curative intent [3].

No routine preoperative biliary drainage. Despite the deep jaundice, I would not routinely drain the biliary tree before surgery. The van der Gaag NEJM 2010 randomised trial showed that PBD increased serious complications from 39 to 74 per cent compared with early surgery. PBD is reserved for cholangitis, delayed surgery, or neoadjuvant therapy [6].

Surgery and adjuvant therapy. Pancreaticoduodenectomy (Whipple) followed by adjuvant chemotherapy (gemcitabine-based or FOLFIRINOX depending on fitness). Surgery is the only chance of cure. [1]

Palliative pathway if unresectable. If staging laparoscopy reveals metastases, shift to ERCP biliary stenting (self-expanding metal stent), palliative chemotherapy, celiac plexus neurolysis for pain, and early palliative care involvement. [1]

Discussion questions

Examiner: "Why does this patient have pale stools and dark urine?" Obstruction of the common bile duct prevents conjugated bilirubin from reaching the gut. It refluxes into the bloodstream (producing conjugated hyperbilirubinaemia) and is excreted by the kidney (dark, tea-coloured urine). Because no bilirubin reaches the intestine, stercobilin is not formed and the stools become acholic (pale, clay-coloured). The pruritus is caused by bile salt deposition in the skin. [1]

Examiner: "How reliable is Courvoisier sign?" Courvoisier sign — a palpable, non-tender gallbladder in a jaundiced patient — has a low sensitivity (about 26 to 55 per cent) but a moderate-to-high specificity (83 to 90 per cent) for malignancy. The mechanism is that malignancy causes slow, progressive obstruction of a thin-walled, compliant gallbladder, allowing distension, whereas recurrent stone disease thickens and fibroses the gallbladder wall so it cannot distend. Its absence does not exclude malignancy, but its presence, as in this patient, strongly suggests it [5].

Examiner: "What are the limitations of CA 19-9, and how would you interpret the level of 420?" CA 19-9 is falsely elevated in benign biliary obstruction, cholangitis, and cirrhosis, so a moderate elevation in an obstructed patient is not diagnostic. It is also falsely normal in Lewis-antigen-negative individuals (5 to 10 per cent of the population). The markedly elevated level here (420, more than ten times the upper limit) in the context of a pancreatic head mass is strongly suggestive of malignancy, but the diagnosis is confirmed by tissue. CA 19-9 is principally a monitoring marker for treatment response and recurrence [4].

Examiner: "Would you drain his biliary tree before the Whipple, and why or why not?" No. The van der Gaag NEJM 2010 randomised trial showed that routine preoperative biliary drainage increased serious complications from 39 to 74 per cent compared with early surgery, with many complications (post-ERCP pancreatitis, cholangitis, stent occlusion) related to the procedure itself. I would reserve PBD for cholangitis, when surgery is delayed, or for neoadjuvant therapy. I would proceed to early surgery with the coagulopathy corrected and the patient optimised [6].

Examiner: "What is the double-duct sign and what does it mean?" The double-duct sign is the simultaneous dilatation of both the common bile duct and the pancreatic duct on imaging, seen upstream of a pancreatic head mass that obstructs both ducts. It is highly suggestive of pancreatic head adenocarcinoma and is a key radiological clue, though it can rarely be seen with other periampullary tumours or chronic pancreatitis. In this patient, the double-duct sign with a pancreatic head mass and the elevated CA 19-9 makes pancreatic adenocarcinoma the overwhelming diagnosis [3].

Short case — focused abdominal examination

Instruction

"Examine this patient's abdomen. He is jaundiced." [1]

Systematic examination routine

1. End of bed inspection. Assess for the depth of jaundice (scleral icterus, then cutaneous), scratch marks and excoriations (pruritus), cachexia, and the stigmata of chronic liver disease (spider naevi, palmar erythema, gynaecomastia, muscle wasting). Note any lines, drains, or surgical scars.
2. Hands and arms. Look for clubbing, palmar erythema, Dupuytren contracture, asterixis (hepatic encephalopathy), and a liver flap.
3. Face and neck. Scleral icterus, conjunctival pallor, parotid enlargement, and Virchow's node (left supraclavicular, Troisier sign, suggesting abdominal malignancy).
4. Abdominal inspection. Distension, scars, visible masses, caput medusae.
5. Palpation. Begin lightly for tenderness and guarding, then deep palpation for hepatosplenomegaly, a palpable gallbladder (Courvoisier sign), an epigastric mass (pancreatic tumour), and a ballotable kidney. Check for shifting dullness and a fluid thrill (ascites).
6. Percussion and auscultation. Percuss the liver span and for shifting dullness. Auscultate bowel sounds and for a hepatic bruit. [1]

Key signs this patient demonstrates

• Deep scleral and cutaneous icterus.
• Scratch marks and excoriations on the forearms and back (pruritus).
• A palpable, non-tender, smooth, distended gallbladder (Courvoisier sign).
• A firm, poorly defined epigastric mass (pancreatic head tumour).
• No stigmata of chronic liver disease (excluding a hepatocellular cause).
• No ascites or hepatosplenomegaly. [1]

Presentation template

"Doctor, I examined Mr RH's abdominal system. He is deeply icteric with scratch marks consistent with pruritus. The abdomen is soft with a palpable, non-tender gallbladder in the right upper quadrant (Courvoisier sign) and a firm epigastric mass. There is no hepatosplenomegaly, no shifting dullness, and no stigmata of chronic liver disease. These findings are consistent with obstructive jaundice from a malignant distal biliary obstruction, most likely a pancreatic head tumour. I would review the imaging, obtain tissue by EUS-FNA, stage for resectability, and check the coagulation before any intervention." [1]

Discussion — differential, imaging strategy, and cholangitis

Examiner: "How would you distinguish obstructive from hepatocellular jaundice at the bedside?" Obstructive jaundice produces pale stools, dark urine, and pruritus, with Courvoisier sign or an abdominal mass suggesting a distal obstruction. Hepatocellular jaundice is associated with the stigmata of chronic liver disease (spider naevi, palmar erythema, ascites, asterixis) and may have a higher transaminase rise relative to the ALP. The definitive distinction is biochemistry (the ALP-to-transaminase ratio) and imaging (ductal dilatation indicates obstruction). [1]

Examiner: "Outline the imaging strategy." Ultrasound first-line (assesses gallbladder, stones, and CBD dilatation); MRCP for the gold-standard non-invasive biliary tree (sensitivity above 90 per cent for stones and strictures); triple-phase CT for the pancreatic mass and staging for resectability (vascular encasement, metastases); EUS-FNA for tissue; and ERCP for therapeutic intervention (stone extraction, stenting, sphincterotomy). The key is not to use ERCP diagnostically when MRCP can answer the question, because ERCP carries a significant complication rate [2].

Examiner: "How would you recognise and manage acute cholangitis in this patient if he developed fever and rigors?" I would apply the Tokyo Guidelines 2018 diagnostic criteria: systemic inflammation (fever, high WCC, CRP elevated) plus cholestasis (jaundice, abnormal LFTs) plus imaging (biliary dilatation or a cause). I would grade the severity to time the drainage: Grade III (organ dysfunction) needs emergent drainage, Grade II (moderate, two of high fever, bilirubin above 5 mg per dL, age above 75, high WCC, low albumin) needs early drainage within 48 hours, and Grade I (mild) needs antibiotics first with drainage if no response within 24 hours. Management is resuscitation, broad-spectrum antibiotics (piperacillin-tazobactam) after blood cultures, and urgent biliary drainage by ERCP. The principle is that antibiotics alone cannot sterilise an obstructed, pressurised biliary tree [1].

Examiner: "What is the prognosis of pancreatic head cancer?" Pancreatic ductal adenocarcinoma has a dismal prognosis: overall five-year survival is under 10 per cent, and only 15 to 20 per cent of patients present with resectable disease. Even after a successful Whipple, the median survival is 18 to 24 months. The best chance of cure is complete surgical resection with negative margins followed by adjuvant chemotherapy. For unresectable or metastatic disease, the prognosis is measured in months, and the focus shifts to palliation [3].